Basic Information
| LncRNA/CircRNA Name | lncRNA-BX111 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qPCR, Western blot, ChIP, RIP, Luciferase reporter assays, etc. |
| Sample | normal human pancreatic cell line (HPDE). four pancreatic cancer cell lines (SW1990, PANC-1, BxPC-3, AsPC1). noncancerous pancreatic (NP) and pancreatic cancer (PC) tissues, |
| Expression Pattern | up-regulated |
| Function Description | Taken together, our findings implicate a hypoxia-induced lncRNA contributes to metastasis and progression of pancreatic cancer, and suggest BX111 might be applied as a potential biomarker and therapeutic target for pancreatic cancer. Results also suggested that ZEB-1 and other regulators of EMT may maintain drug resistance in human PC cells.The clinical samples of pancreatic cancer further confirmed a positive association between BX111 and ZEB1. Moreover, high BX111 expression was correlated with late TNM stage, lymphatic invasion and distant metastasis, as well as short overall survival time in patients. |
| Pubmed ID | 29970904 |
| Year | 2018 |
| Title | Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. |
External Links
| Links for lncRNA-BX111 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |